by Symmetron | Jan 21, 2019
juvenile idiopathic arthritis  Cost-utility of tocilizumab in the treatment of systemic juvenile idiopathic arthritis in Finland Annals of the Rheumatic Diseases. 2013;71:258-259 Authors Hallinen T, Soini EJ, Diamantopoulos A, Dejonckheere F, Vihervaara V, Hautala A,...
Recent Comments